Comparative Pharmacology
Head-to-head clinical analysis: PATHILON versus TOLTERODINE TARTRATE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: PATHILON versus TOLTERODINE TARTRATE.
PATHILON vs TOLTERODINE TARTRATE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Anticholinergic agent that competitively inhibits muscarinic acetylcholine receptors, decreasing gastrointestinal motility and gastric acid secretion.
Competitive antagonist of muscarinic acetylcholine receptors (M1, M2, M3, M4, M5) with relative selectivity for the bladder over salivary glands. Reduces detrusor muscle contractility and bladder pressure.
1-2 mg orally every 4-6 hours; maximum 12 mg/day. Alternatively, IM: 1-2 mg every 4-6 hours.
2 mg orally twice daily. May be reduced to 1 mg orally twice daily based on tolerability.
None Documented
None Documented
Terminal elimination half-life approximately 2-4 hours; may be prolonged in elderly or patients with hepatic/renal impairment.
Terminal elimination half-life is 2-3 hours in extensive metabolizers (CYP2D6) and approximately 9 hours in poor metabolizers. In clinical context, dosing interval is adjusted in poor metabolizers (e.g., 2 mg twice daily reduced to 2 mg once daily).
Primarily renal (50-70% as unchanged drug and metabolites); biliary/fecal (20-30%); minor metabolism via hepatic ester hydrolysis.
Renal (77%) and fecal (17%): approximately 14% as unchanged tolterodine, 51% as the active 5-hydroxymethyl metabolite, and 12% as other metabolites. Biliary excretion contributes minimally.
Category C
Category A/B
Anticholinergic
Anticholinergic